CA2811454C - 2-(r2-thio)-10-[3-(4-r1-piperazin-1-yl)propyl]-10h-phenothiazine for treating a b-amyloidopathy or an alpha-synucleopathy, and method for the diagnosis or prediagnosis thereof - Google Patents
2-(r2-thio)-10-[3-(4-r1-piperazin-1-yl)propyl]-10h-phenothiazine for treating a b-amyloidopathy or an alpha-synucleopathy, and method for the diagnosis or prediagnosis thereof Download PDFInfo
- Publication number
- CA2811454C CA2811454C CA2811454A CA2811454A CA2811454C CA 2811454 C CA2811454 C CA 2811454C CA 2811454 A CA2811454 A CA 2811454A CA 2811454 A CA2811454 A CA 2811454A CA 2811454 C CA2811454 C CA 2811454C
- Authority
- CA
- Canada
- Prior art keywords
- abcc1
- phenothiazine
- piperazin
- thio
- propyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 title claims abstract 8
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000002490 cerebral effect Effects 0.000 claims abstract 7
- 208000032859 Synucleinopathies Diseases 0.000 claims abstract 3
- 230000000694 effects Effects 0.000 claims abstract 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract 3
- 102000004169 proteins and genes Human genes 0.000 claims abstract 3
- 239000013543 active substance Substances 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 101000969812 Homo sapiens Multidrug resistance-associated protein 1 Proteins 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
- C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
- C07D279/28—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom with other substituents attached to the ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
- C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2870626A CA2870626C (en) | 2010-09-07 | 2011-08-30 | 2-(r2-thio)-10-[3-(4-r1-piperazin-1-yl)propyl]-10h-phenothiazine for treating a beta-amyloidopathy or an alpha-synucleopathy, and method for the diagnosis or prediagnosis thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010044561 | 2010-09-07 | ||
| DE102010044561.4 | 2010-09-07 | ||
| PCT/EP2011/064893 WO2012031941A2 (de) | 2010-09-07 | 2011-08-30 | 2-(R²-THIO)-10-[3-(4-R1-PIPERAZIN-1-YL)PROPYL]-10H-PHENOTHIAZINE ZUR BEHANDLUNG EINER β-AMYLOIDOPATHIE ODER ALPHA-SYNUCLEOPATHIE SOWIE VERFAHREN ZU DEREN DIAGNOSE ODER PRÄDIAGNOSE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2870626A Division CA2870626C (en) | 2010-09-07 | 2011-08-30 | 2-(r2-thio)-10-[3-(4-r1-piperazin-1-yl)propyl]-10h-phenothiazine for treating a beta-amyloidopathy or an alpha-synucleopathy, and method for the diagnosis or prediagnosis thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2811454A1 CA2811454A1 (en) | 2012-03-15 |
| CA2811454C true CA2811454C (en) | 2017-03-28 |
Family
ID=44645670
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2811454A Active CA2811454C (en) | 2010-09-07 | 2011-08-30 | 2-(r2-thio)-10-[3-(4-r1-piperazin-1-yl)propyl]-10h-phenothiazine for treating a b-amyloidopathy or an alpha-synucleopathy, and method for the diagnosis or prediagnosis thereof |
| CA2870626A Active CA2870626C (en) | 2010-09-07 | 2011-08-30 | 2-(r2-thio)-10-[3-(4-r1-piperazin-1-yl)propyl]-10h-phenothiazine for treating a beta-amyloidopathy or an alpha-synucleopathy, and method for the diagnosis or prediagnosis thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2870626A Active CA2870626C (en) | 2010-09-07 | 2011-08-30 | 2-(r2-thio)-10-[3-(4-r1-piperazin-1-yl)propyl]-10h-phenothiazine for treating a beta-amyloidopathy or an alpha-synucleopathy, and method for the diagnosis or prediagnosis thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20130184268A1 (enExample) |
| EP (3) | EP3097914A3 (enExample) |
| JP (2) | JP6084924B2 (enExample) |
| CN (2) | CN106243060A (enExample) |
| BR (1) | BR112013005472A2 (enExample) |
| CA (2) | CA2811454C (enExample) |
| DE (2) | DE102010062810B4 (enExample) |
| DK (2) | DK2693216T3 (enExample) |
| ES (2) | ES2605705T3 (enExample) |
| MX (1) | MX357521B (enExample) |
| PL (2) | PL2614060T3 (enExample) |
| RU (2) | RU2016118021A (enExample) |
| WO (1) | WO2012031941A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4223297A3 (en) | 2016-07-25 | 2023-11-15 | WisTa Laboratories Ltd. | Administration and dosage of diaminophenothiazines |
| FI3826639T3 (fi) | 2018-07-26 | 2024-10-30 | Wista Lab Ltd | Diaminofenotiatsiinien optimoitu annostus populaatioille |
| CN115279915A (zh) * | 2020-03-16 | 2022-11-01 | 德瑞生物医药股份有限公司 | 依托泊苷糖苷、其制备方法及其作为抗癌药物的用途 |
| CA3242478A1 (en) * | 2022-01-04 | 2023-07-13 | Immungenetics Ag | Specific dosage of phenothiazine compounds for use in treatment or prevention of alzheimer's dementia |
| CA3268498A1 (en) * | 2022-10-18 | 2024-04-25 | Immungenetics Ag | IDENTIFICATION OF A SUBJECT SUFFERING FROM ALZHEIMER'S DISEASE OR PRESENTING A RISK OF DEVELOPING ALZHEIMER'S DISEASE |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH365379A (de) * | 1956-04-18 | 1962-11-15 | Sandoz Ag | Verfahren zur Herstellung von neuen, in 3-Stellung mit einer einwertigen Schwefelfunktion substituierten Phenothiazinen |
| BE568701A (enExample) * | 1957-06-18 | |||
| US3621097A (en) * | 1970-03-30 | 1971-11-16 | Jan Marcel Didier Aron Samuel | Method and compositions for treatment of mental illness |
| US4471116A (en) * | 1982-07-28 | 1984-09-11 | Hoffmann-La Roche Inc. | Substituted (10H-phenothiazin-10-L)-propyl-1-piperazines |
| US6566368B2 (en) * | 1994-04-22 | 2003-05-20 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage form for ameliorating male erectile dysfunction |
| EP0778773A1 (en) * | 1994-08-08 | 1997-06-18 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes |
| DE4430091A1 (de) * | 1994-08-25 | 1996-02-29 | Bayer Ag | Verwendung von N-substituierten Phenothiazinen |
| DE60307049T2 (de) * | 2003-04-25 | 2007-02-08 | Neuro3D | Verwendung von Piperazin- Phenothiazin- Derivaten zur Herstellung eines Arzneimittels mit neuroprotektiven und/oder neurotropischen Wirkungen auf das ZNS und/oder PNS |
| DE102005014142B4 (de) * | 2005-03-23 | 2006-11-09 | Hennig Arzneimittel Gmbh & Co. Kg | Pelletförmige Retardzubereitung gegen Schwindel |
| WO2007062862A2 (en) * | 2005-12-02 | 2007-06-07 | Ludwig Maximilians Universität München | Use of calmodulin inhibitors for the treatment of neurodegenerative disorders |
| DK2457904T3 (en) * | 2006-07-11 | 2015-01-12 | Wista Lab Ltd | Methods for the synthesis and / or purification of the compounds diaminophenothiazinium |
| CN101627049B (zh) * | 2006-11-10 | 2012-09-05 | 卡拉治疗学股份有限公司 | 合成酞酰胺 |
| GB0701970D0 (en) * | 2007-02-01 | 2007-03-14 | Wilson Stuart | Treatment of protein aggregation diseases |
| WO2008133884A2 (en) * | 2007-04-23 | 2008-11-06 | Combinatorx, Incorporated | Methods and compositions for the treatment of neurodegenerative disorders |
| EP2285374B1 (en) * | 2008-04-29 | 2019-09-18 | Pharnext | Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate |
| LT2282778T (lt) * | 2008-04-29 | 2017-06-26 | Pharnext | Nauji terapijos būdai, gydant alzheimerio ligą ir susijusius sutrikimus per angiogenezės moduliaciją |
| ES2410930T3 (es) * | 2008-04-29 | 2013-07-03 | Pharnext | Nuevos enfoques terapéuticos para tratar la enfermedad de alzheimer y trastornos relacionados mediante la modulación de la respuesta de estrés celular |
| US9399032B2 (en) * | 2009-05-14 | 2016-07-26 | The General Hospital Corporation | Methods and compositions for treating degenerative and ischemic disorders |
-
2010
- 2010-12-10 DE DE102010062810.7A patent/DE102010062810B4/de not_active Expired - Fee Related
-
2011
- 2011-08-30 BR BR112013005472-7A patent/BR112013005472A2/pt not_active Application Discontinuation
- 2011-08-30 RU RU2016118021A patent/RU2016118021A/ru not_active Application Discontinuation
- 2011-08-30 PL PL11755294T patent/PL2614060T3/pl unknown
- 2011-08-30 DK DK13190419.5T patent/DK2693216T3/en active
- 2011-08-30 US US13/821,515 patent/US20130184268A1/en not_active Abandoned
- 2011-08-30 ES ES11755294.3T patent/ES2605705T3/es active Active
- 2011-08-30 CN CN201610631393.5A patent/CN106243060A/zh active Pending
- 2011-08-30 JP JP2013527544A patent/JP6084924B2/ja active Active
- 2011-08-30 EP EP16180106.3A patent/EP3097914A3/de not_active Withdrawn
- 2011-08-30 PL PL13190419T patent/PL2693216T3/pl unknown
- 2011-08-30 EP EP13190419.5A patent/EP2693216B1/de active Active
- 2011-08-30 CN CN201180053670.4A patent/CN103237802B/zh active Active
- 2011-08-30 MX MX2013002612A patent/MX357521B/es active IP Right Grant
- 2011-08-30 DK DK11755294.3T patent/DK2614060T3/da active
- 2011-08-30 WO PCT/EP2011/064893 patent/WO2012031941A2/de not_active Ceased
- 2011-08-30 RU RU2013110018/04A patent/RU2587154C2/ru active
- 2011-08-30 CA CA2811454A patent/CA2811454C/en active Active
- 2011-08-30 CA CA2870626A patent/CA2870626C/en active Active
- 2011-08-30 ES ES13190419T patent/ES2701453T3/es active Active
- 2011-08-30 EP EP11755294.3A patent/EP2614060B1/de active Active
- 2011-08-30 DE DE102011053114A patent/DE102011053114A1/de not_active Ceased
-
2014
- 2014-09-29 US US14/499,918 patent/US9370523B2/en active Active
-
2015
- 2015-09-08 US US14/847,089 patent/US20150374711A1/en not_active Abandoned
-
2016
- 2016-07-01 JP JP2016131781A patent/JP6426663B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2811454C (en) | 2-(r2-thio)-10-[3-(4-r1-piperazin-1-yl)propyl]-10h-phenothiazine for treating a b-amyloidopathy or an alpha-synucleopathy, and method for the diagnosis or prediagnosis thereof | |
| Krohn et al. | Cerebral amyloid-β proteostasis is regulated by the membrane transport protein ABCC1 in mice | |
| CA2633573C (en) | Inhibition of tau-tau-association | |
| CN101460157B (zh) | 蛋白聚集抑制剂 | |
| US8741883B2 (en) | Compounds and methods for the diagnosis and treatment of amyloid associated diseases | |
| JP6417324B2 (ja) | τリン酸化を阻害する方法 | |
| US20100303805A1 (en) | Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases | |
| Kuret | Detection and reduction of neurofibrillary lesions | |
| US20240398783A1 (en) | Compounds and Pharmaceutical Compositions Comprising Inhibitors of Amyloid Peptide Interactions with Glycosaminoglycans, Methods of Treatment and Use Thereof | |
| AU2023346185A1 (en) | Thiazole derivatives as tau aggregation inhibitors | |
| WO2011051521A2 (es) | Utilización del gambierol para el tratamiento y/o la prevención de enfermedades neurodegenerativas relacionadas con tau y beta-amiloide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130529 |